Perioperative management of cardiovascular surgical procedures requiring cardiopulmonary bypass (CPB) in patients with hemophilia A poses a clinical challenge in coagulation management. Use of CPB requires the administration of an anticoagulant, usually unfractionated heparin, and also causes dilutional coagulopathy, platelet dysfunction or platelet consumption coagulopathy. Hypothermia and activation of the inflammatory cascade also affect coagulation. The effects of CPB on circulating levels of factor VIII have not been clearly defined. In this review, the effects of CPB and hemodilution on FVIII are shown in a case presentation, and perioperative laboratory testing in patients with hemophilia A having cardiac surgery is discussed along with perioperative and postoperative coagulation management.
SoucieJMEvattBJacksonD.Occurrence of hemophilia in the US. Am J Hematol. 1998;59:288-294.
2.
FerrarisVABoralLICohenAJSmythSSWhiteGC2nd. Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B. Cardiol Rev. 2012;23:53-68.
3.
KulkarniRSoucieJMEvattBL.Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol. 2005;79:36-42.
4.
SharathkumarAASoucieJMTrawinskiBGreistAShapiroAD.Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia. 2011;17:597-604.
5.
RossiMJayaramRSayeedR.Do patients with hemophilia undergoing cardiac surgery have good surgical outcomes?Interact Cardiovasc Thorac Surg. 2011;13:320-331.
KarkoutiKMcCluskeySASyedSPazaratzCPoonawalaHCrowtherMA.The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study. Anesth Analg. 2010;110:1533-1540.
8.
HazendonkHCAMLockJMathôtRAAet al. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. J Thromb Haemost. 2016;14:468-478.
9.
VandewieleKBoveTDe SomerFMJJet al. The effect of retrograde autologous priming volume on haemodilution and transfusion requirements during cardiac surgery. Interact Cardiovasc Thorac Surg. 2013;16:778-783.
TangMWierupPTerpKSorensonB.Cardiac surgery in patients with haemophilia. Haemophilia. 2009;15:101-107.
12.
YuanSFerrellCChandlerWL.Comparing the prothrombin time INR versus the APTT to evaluate the coagulopathy of acute trauma. Thromb Res. 2007;120:29-37.
13.
PivalizzaEGEscobarMA.Thrombelastography-guided factor VIIa therapy in a surgical patient with severe hemophilia and factor VIII inhibitor. Anesth Analg. 2008;107:398-401.
14.
YoungG1SørensenBDargaudYNegrierCBrummel-ZiedinsKKeyNS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013;121:1944-1950.
Manco-JohnsonMJNussRJacobsonLJ.Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. J Lab Clin Med. 2000;136:74-79.
17.
GerhardtMAGreenbergCSSlaughterTFSmithMS.Factor XII deficiency and cardiopulmonary bypass: use of a novel modification of the activated clotting time to monitor anticoagulation. Anesthesiology. 1997;87:990-992.
18.
KosterADespotisGGruendelMet al. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. Anesth Analg. 2002;95:26-30.
19.
AinleFNPrestonRJJenkinsPVet al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood. 2009;114:1658-1665.
20.
MochizukiTOlsonPJSzlamFRamsayJGLevyJH.Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781-785.
21.
BhavePMcGiffinDShawJet al. Guide to performing cardiac surgery in patients with hereditary bleeding disorders. J Card Surg. 2015;30:61-69.
22.
MacKinlayNTaperJRenissonFRickardK.Cardiac surgery and catheterization in patients with haemophilia. Haemophilia. 2000;6:84-88.
23.
LisonSSpannaglMDietrichW.Hemophilia A in cardiac operations: a model of reduced thrombin generation. Ann Thorac Surg. 2011;91:1606-1608.
24.
StineKCBectonDL.Use of factor VIII replacement during open heart surgery in a patient with haemophilia A. Haemophilia. 2006;12:435-436.
25.
De BelsDDemeereJLDugauquierJLouisPVan der VorstE.Continuous infusion of factor VIIIC during heart surgery in a patient with haemophilia A. Eur J Anaesthesiol. 2004;21:984-986.
26.
FurutachiAFurukawaK.Total arch replacement for acute aortic dissection (Stanford A) in a patient with hemophilia A. Ann Thorac Surg. 2012;93:e61-e62.
27.
DiplarisKTKarfisEAet al. Acute type-a dissection in a patient with severe hemophilia A. J Cardiothorac Vasc Anesth. 2012;26:660-663.
28.
BatorovaAMartinowitzU.Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol. 2000;110:715-720.
29.
LeviMCromheeckeMEDe JongeEet al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999;354:1940-1947.
30.
WeberCFGörlingerKMeiningerDet al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012;117:531-547.
31.
MannucciPM.Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia. 2000;6:60-67.
32.
ChowdaryPSaaymanAGPaulusUFindlayGPCollinsPW.Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol. 2004;125:69-73.
33.
MullerMCAStraatMMeijersJCMet al. Fresh frozen plasma transfusion fails to influence the hemostatic balance in critically ill patients with a coagulopathy. J Thromb Haemost. 2015;13:989-997.
34.
RefaaiMAGoldsteinJNLeeMLDurnBLMillingTJJrSarodeR.Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal. Transfusion. 2015;55:2722-2729.
35.
Rahe-MeyerNSolomonCHankeAet al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology. 2013;118:40-50.
36.
RanucciMBaryshnikovaECrapelliGBRahe-MeyerNMenicantiLFrigiolaA; Surgical Clinical Outcome REsearch (SCORE) Group. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc. 2015;4:e002066.
37.
Rahe-MeyerNLevyJHMazerCDet al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. Br J Anaesth. 2016;117:41-51.
38.
CaudillJSNicholsWLPlumhoffEAet al. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. Transfusion. 2009;49:765-770.
39.
CookeJVHollandPVShulmanNR.Cryoprecipitate concentrates of factor VIII for surgery in hemophiliacs. Ann Int Med. 1968;68:39-47.
40.
TurecekPLVaradiKGritschHSchwarzHP.FEIBA®: mode of action. Haemophilia. 2004;10(suppl 2):3-9.
41.
HoffmanMDargaudY.Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost. 2012;10:1478-1485.
42.
BalsamLBTimekTAPelletierMP.Factor eight inhibitor bypassing activity (FEIBA) for refractory bleeding in cardiac surgery: review of clinical outcomes. J Card Surg. 2008;23:614-621.
43.
SongHKTibayanFAKahlEAet al. Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. J Thorac Cardiovasc Surg. 2014;147:1036-1040.
44.
TanakaKAMazzeffiMAGrubeMOgawaSChenEP.Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion. 2013;53:920-921.
45.
OrtmannEBesserMWSharplesLDet al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg. 2015;121:26-33.
46.
DunkleySPhillipsLMcCallPet al. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. Ann Thorac Surg. 2008;85:836-844.
47.
RaoVKLobatoRLBartlettBet al. Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery. J Cardiothorac Vasc Anesth. 2014;28:1221-1226.
48.
AledortLM.Factor VIII inhibitor bypassing activity (FEIBA)—addressing safety issues. Haemophilia. 2008;14:39-43.
49.
EkezueBFSridharGOvanesovMVet al. Clotting factor product administration and same-day occurrence of thrombotic events, as recorded in a large healthcare database during 2008-2013. J Thromb Haemost. 2015;13:2168-2179.
50.
IngerslevJSørensenB.Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol. 2011;155:256-262.
51.
HillisLDSmithPKAndersonJLet al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. Executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2610-2642.
52.
SchutgensREGTuinenburgARoosendaalGGuyomiSHMauser-BunschotenEP. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia. 2009;15:952-958.
53.
MannucciPM.Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia. Expert Opin Pharmacother. 2012;13:505-510.
54.
GouldMKGarciaDAWrenSHet al. American College of Chest Physicians. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e227S-e277S.
55.
CloseVPurohitMTanosMHunterS.Should patients post-cardiac surgery be given low molecular weight heparin for DVT prophylaxis?Interact Cardiovasc Thorac Surg. 2006;5:624-629.
